Ref ID: 2746
Author:
J. STONE1, S. HOLLAND1, P. WICKERSHAM1, P. DEUTSCH1, G. WINCHELL1, M. HESNEY1, R. MILLER1, A. FREEMAN1, S. DILZER2, K. LASSETER2
Author address:
1Merck Research Laboratories, West Point, PA, 2Clinical Pharmacology Associates, Miami, FL.
Full conference title:
ICAAC 41st
Abstract:
Background: Caspofungin (CancidasTM, MK-0991, L-743,872) is a parenteral antifungal agent that inhibits the synthesis of 1,3 b-D glucan, an essential component of the fungal cell wall.
Methods: The potential for drug interactions between caspofungin and tacrolimus (FK-506) was evaluated in a placebo-controlled, randomized, Phase I study. Part (1) was a 2-period, parallel-panel study in which healthy subjects received tacrolimus (2 doses of 0.1 mg/kg oral capsules administered 12 hours apart, n=12) or placebo (n=5) alone in Period 1 and again on Day 10 of caspofungin 70 mg IV daily in Period 2. In Part (2), parallel panels of healthy subjects received tacrolimus (2 doses of 0.1 mg/kg 12 hours apart, n=8) or placebo (n=8) on Days 1 and 10 of caspofungin 50 mg IV daily.
Results: The geometric mean ratio (90% CI) for caspofungin plasma AUC(0-24hr) under coadministration relative to administration alone was 1.00 (0.96, 1.04) for Part (1) and 1.05 (0.96, 1.15) for Part (2), based on a mixed-model analysis that evaluated pharmacokinetic data obtained on Days 9 and 10 in both the coadministration and the placebo-control panels. The geometric mean ratio (90% CI) for tacrolimus whole blood AUC(0-12hr) in Period 2 (coadministration) relative to Period 1 (administration alone) was 0.80 (0.72, 0.89) for Part (1), based on a combined analysis of morning and evening doses. Reductions of similar magnitude were also seen for tacrolimus CMAX and C12hr. Conclusions: Tacrolimus does not alter the pharmacokinetics of caspofungin. Caspofungin modestly reduces whole blood concentrations of tacrolimus. For patients receiving both therapies, standard monitoring of tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are recommended.
Abstract Number: NULL
Conference Year: 2001
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Nada Kraševec , Irena Lukanèiè , Tatjana Milunović , Marija An ur Lasnik , Mojca
Benèina , Vladka Gaberc Porekar , Radovan Komel2011
76)
n/a
-
v
M.H. Pedersen, I. Borodina, J.C.
Frisvad and I. Søndergaard2011
75)
n/a
-
v
Andreas Thywissen1, 3, Thorsten Heinekamp1,
Hans-Martin Dahse2, Peter F. Zipfel2, 3, and Axel A. Brakhage1,2011
NULL
n/a
-
v
Martha B. Arnaud 1, Jonathan Binkley 1, Gustavo Cerqueira 2, Marcus C. Chibucos 2, Maria C. Costanzo 1, Jonathan Crabtree 2, Diane
O. Inglis 1, Joshua Orvis 2, Prachi Shah 1, Marek S. Skrzypek 1, Gail Binkley 1, Stuart R. Miyasato 1, Jennifer Russo2011
NULL
n/a
-
v
Suman Pakala, Vinita Joardar, Nikhat Zafar, Suchitra Pakala,
Sean Murphy, Natalie Fedorova and William Nierman J. Craig Venter Institute,2011
72)
n/a
-
v
Sandra Bruns , Mike Hasenberg , Olaf Kniemeyer , Andreas Thywißen , Vishukumar Aimanianda , Jean-Paul Latgé , Matthias Gunzer , Axel
Brakhage2011
71)
n/a
-
v
Suman Pakala, Jessica Hostetler, Suchitra Pakala, Vinita
Joardar, Paul Bowyer, David Denning, William C. Nierman, Natalie D. Fedorova. J. Craig2011
70)
n/a
-
v
Carolyn J. Worthington , Bruce W. Horn , Geromy G. Moore , James T.
Monacell , Rakhi Singh , Eric A. Stone , Ignazio Carbone2011
69)
n/a
-
v
Rodrigo A. Olarte , Bruce W. Horn , James T. Monacell ,
Rakhi Singh , Eric A. Stone , Ignazio Carbone .2011
68)
n/a
-
v
Clay, Wang,; Yi-Ming, Chiang; Berl, Oakley,; Nancy, Keller,;
Kenneth, Bruno; Scott, Baker; Kristen, Meyer; Michael, Praseuth; Edyta, Szewczyk; Ashley, Davidson; Ruth, Entwistle; James, Sanchez2;
Manmeet, Ahuja; Jin Woo, Bok,; Jonathan, Palmer2011
65)
n/a